Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Non-Small Cell Lung Carcinoma

Non-Small Cell Lung Carcinoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Non-Small Cell Lung Carcinoma

36 trials tracked for Non-Small Cell Lung Carcinoma: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 1113 citations.

36Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 8 Phase 2 19 Phase 1 2 Other / NA 5
  1. Phase 3 Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed · 1,113 cited
  2. Phase 3 Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) Completed · 660 cited
  3. Phase 3 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy Completed · 155 cited
  4. Phase 3 Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study Completed · 57 cited
  5. Phase 4 Study of Nivolumab for Advanced Cancers in India Completed
  6. Phase 4 SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Completed
Show 30 more trials
  1. Phase 3 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) Completed
  2. Phase 3 Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Completed
  3. Phase 3 Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer Completed
  4. Phase 3 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Completed
  5. Phase 2 Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Completed
  6. Phase 2 Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study Completed
  7. Phase 2 Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer Completed
  8. Phase 2 A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. Completed
  9. Phase 2 A Study in Non-Small Cell Lung Cancer Completed
  10. Phase 2 A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) Completed
  11. Phase 2 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Completed
  12. Phase 2 A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients Completed
  13. Phase 2 A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations Completed
  14. Phase 2 Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy Completed
  15. Phase 2 A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment Completed
  16. Phase 2 Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC Completed
  17. Phase 2 Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer Completed
  18. Phase 2 Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... Completed
  19. Phase 2 Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer Completed
  20. Phase 2 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed
  21. Phase 2 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer Completed
  22. Phase 2 Neoadjuvant Pembrolizumab Completed
  23. Phase 2 Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence Completed
  24. Phase 1 A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) Completed
  25. Phase 1 The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer Completed
  26. N/A Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns Completed
  27. N/A A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled Completed
  28. N/A Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy Completed
  29. N/A Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer Completed
  30. N/A Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer Completed

Showing the 36 most-cited and recently-updated of 36 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Non-Small Cell Lung Carcinoma: what the trials found

Pembrolizumab has demonstrated significant clinical activity across multiple trials. In a Phase 3 study, it showed superior progression-free survival (PFS) at 6 months (62.1% vs 50.3%, p<0.001), higher overall survival (OS) (70.3% vs 54.8%, p=0.002), and a significantly higher objective response rate (ORR) (44.8% vs 27.8%, p=0.0011) 5. Another Phase 3 trial reported superior PFS (8.8 months vs 4.9 months, p<0.0001) and a significantly higher ORR (47.6% vs 18.9%, p<0.0001) 6. In specific cohorts, Pembrolizumab showed a significant improvement in ORR (55.0% vs 28.6%, p=0.0016) and PFS (24.5 months vs 9.9 months, p=0.00252) 22.

Other established therapies include Nivolumab and various chemotherapeutic agents. Nivolumab showed a higher number of responders in one trial compared to the control group (87 vs 58, p=0.0066) 12, though its OS results were not statistically significant in another study 7. Albumin-bound paclitaxel demonstrated a significantly higher rate of confirmed complete or partial response (33% vs 25%, p=0.005) 10, while standard Paclitaxel showed a similar number of responders compared to its control group (87 vs 58, p=0.0066) 12. Pemetrexed was evaluated in Phase 2 trials but did not show statistically significant differences in PFS or ORR compared to controls 20.

Experimental and combination therapies have shown mixed results. The Pembrolizumab/Vibostolimab combination did not reach statistical significance for overall survival across different PD-L1 expression levels 9. One trial of Pembrolizumab showed a higher OS rate (25.9% vs 14.0%) but did not reach statistical significance for PFS 8.

Recent results — preliminary, needs further review

  • Lorlatinib was evaluated in a Phase I/II study, but results are not yet corroborated.
  • Carfilzomib showed an OS rate of 0.59 vs 0.54 at 6 months and a PFS rate of 0.32 vs 0.12 at 6 months, but these findings are not yet corroborated.

For the clinician treating this condition

  • Pembrolizumab is associated with statistically significant improvements in ORR, PFS, and OS across multiple Phase 2 and Phase 3 trials.
  • Albumin-bound paclitaxel shows a statistically significant improvement in the percentage of patients achieving an objective confirmed complete or partial response compared to standard treatments.
  • Nivolumab showed improved response rates in one trial, but its impact on overall survival was not statistically significant.

AI synthesis of 9 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Fissios App plus physiotherapy aims to cut postoperative complications in NSCLC surgery
Oncology RCT
Fissios App plus physiotherapy aims to cut postoperative complications in NSCLC surgery App may help lung cancer patients avoid complications after surgery
This randomized controlled trial protocol will enroll 560 NSCLC patients scheduled for surgery to test whether adding the Fissios App to fac…
A new trial will test if an app can help lung cancer patients avoid complications after surgery. Here's what's planned.
Jun 18, 2026